Novel immunotherapy combinations for genitourinary cancers
/in Dendritic Cells, Hypernephroma, International Publications, Urothelial Carcinoma /von 2020-01-27 / Expert Opin Biol Ther 2020 03;20(3):253-262Suppression of TGF-β and IL-10 receptors on self-differentiated dendritic cells by short-hairpin RNAs enhanced activation of effector T-cells against cholangiocarcinoma cells
/in Dendritic Cells, Gallbladder Cancer, International Publications /von 2020-01-24 / Hum Vaccin Immunother 2020 Oct;16(10):2318-2327Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2020-01-24 / Cancer Immunol. Immunother. 2020 Mar;69(3):477-488Therapeutic Cancer Vaccination with Ex Vivo RNA-Transfected Dendritic Cells-An Update
/in Dendritic Cells, International Publications /von 2020-01-23 / Pharmaceutics 2020 Jan;12(2)Breast cancer stem cell RNA-pulsed dendritic cells enhance tumor cell killing by effector T cells
/in Breast Cancer, Dendritic Cells, International Publications /von 2020-01-23 / Oncol Lett 2020 Mar;19(3):2422-2430Combined proteomics/miRNomics of dendritic cell immunotherapy-treated glioblastoma patients as a screening for survival-associated factors
/in Dendritic Cells, Glioblastoma, International Publications /von 2020-01-16 / NPJ Vaccines 2020;5:5Prophylactic dendritic cell vaccination controls pancreatic cancer growth in a mouse model
/in Dendritic Cells, International Publications, Pancreatic Cancer /von 2020-01-01 / Cytotherapy 2020 01;22(1):6-15Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models
/in Dendritic Cells, International Publications /von 2019-12-05 / Cancer Immunol. Immunother. 2020 Jan;69(1):135-145Engineering dendritic cell vaccines to improve cancer immunotherapy
/in Dendritic Cells, International Publications /von 2019-11-27 / Nat Commun 2019 11;10(1):5408
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de